Vanguard Capital Management
NVCT icon

Vanguard Capital Management’s Nuvectis Pharma NVCT Stock Holding History

Vanguard Capital Management’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16M Buy
872,482
+212,603
+32% +$2.38M ﹤0.01% 2569
2026
Q1 		$5.1M Buy
+659,879
New +$5.65M ﹤0.01% 3048

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Capital Management's NVCT Position: Q2 2026 in Review

Vanguard Capital Management increased its Nuvectis Pharma (NVCT) stake by 32% in Q2 2026, buying an estimated $2.38M and bringing the position to 872,482 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #2569.

Vanguard Capital Management first reported a position in NVCT in Q1 2026 and has held it in 2 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Vanguard Capital Management held 872,482 shares of Nuvectis Pharma worth $16M as of Q2 2026.
  • Vanguard Capital Management bought 212,603 Nuvectis Pharma shares in Q2 2026, an estimated $2.38M.
  • Nuvectis Pharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2569 holding.
  • Vanguard Capital Management first reported a position in Nuvectis Pharma in Q1 2026 and has held it in 2 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.